E Daily Stock Analysis: Novartis AG

Free stock photo of analysis, biochemistry, biology

Image Source: Unsplash

Novartis AG has the ticker symbol NVS and is a member of the Healthcare sector as a generic drug manufacturer. This is my first report on Novartis for this Vista portfolio.  

Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. 

It generates the vast majority of its revenue from the Innovative Medicines segment consisting of global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. 

The company sells its products globally, with the United States representing close to one-third of total revenue.

Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV. 

The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Three key data points gauge dividend equities or funds like Novartis AG:

(1) Price

(2) Dividends

(3) Returns

Those three basic keys best tell whether a company has made, is making, and will make money. 

NVS Price

Novartis AG's price per share closed at $86.30 yesterday. One year ago its price was $83.99. Price per share has increased about 4.4% from the midst of the COVID market slump. 

Should Novartis AG's stock trade in the range of $75.00 to $105.00 this year, its recent $86.30 price might rise by $8.70 to reach $95.00 by April 8, 2022. My estimate is however $ 8.00 lower than the median of five estimates from analysts tracking the stock.

NVS Dividends

Novartis AG's most recent declared annual dividend paid March 15th was $3.20 annually and yields 3.71% at yesterday's $95,00 closing price. NVS has paid annual variable dividends for 29 years.

NVS Returns

Adding the $3.20 annual NVS anticipated dividend to my $8.70 price upside estimate shows an $11.90  potential gross gain, per share, to be reduced by any costs to trade the shares.  

1 2
View single page >> |

Disclaimer: This article is for informational and educational purposes only and should not be construed to constitute investment advice. Nothing contained herein shall constitute a solicitation, ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.